title: Potentiation of nitric oxide-induced apoptosis of MDA-MB-468 cells by farnesyltransferase inhibitor: implications in breast cancer.
abstract: High amounts of nitric oxide (NO) produced by activated macrophages or NO donors are required to induce cytotoxicity and apoptosis in pathogens and tumor cells. High concentrations of NO may lead to nonspecific toxicity thereby limiting the use of NO donors in the treatment of cancer. In this study, we tested the possibility of potentiating the apoptotic action of NO in a human breast cancer cell line, MDA-MB-468, by combining it with a farnesyltransferase inhibitor (FTI), which has been shown to induce apoptosis in some other cancer cell lines with minimal toxicity to normal cells. DETA-NONOate, a long acting NO donor which has a half-life of 20 h at 37 degrees C, was used in this study. DETA-NONOate (1 mM), which releases NO in the range produced by activated macrophages, induced apoptosis after 36 h in MDA-MB-468 cells via cytochrome c release and caspase-9 and -3 activation. FTI (25 microM) potentiated the action of lower concentrations of DETA-NONOate (25-100 microM) by inducing apoptosis in these cells within 24 h by increasing cytochrome c release and caspase-9 and -3 activation. This effect was observed preferentially in the cancer cell lines studied with no apoptosis induction in normal breast epithelial cells. This novel combination of FTI and NO may emerge as a promising approach for the treatment of breast cancer.
authors.affiliation: Department of Obstetrics & Gynecology, Jonsson Comprehensive Cancer Center, University of California School of Medicine, Los Angeles, California 90095-1740, USA.
authors.forename: S
authors.initials: S
authors.lastname: Pervin
authors.forename: R
authors.initials: R
authors.lastname: Singh
authors.forename: C L
authors.initials: CL
authors.lastname: Gau
authors.forename: H
authors.initials: H
authors.lastname: Edamatsu
authors.forename: F
authors.initials: F
authors.lastname: Tamanoi
authors.forename: G
authors.initials: G
authors.lastname: Chaudhuri
mesh_terms: D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors*; D017209:Apoptosis / Q000187:drug effects* / Q000502:physiology; D001943:Breast Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology*; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D051231:Farnesyltranstransferase; D006801:Humans; D009569:Nitric Oxide / Q000493:pharmacokinetics / Q000494:pharmacology*; D020030:Nitric Oxide Donors / Q000493:pharmacokinetics / Q000494:pharmacology; D009603:Nitroso Compounds / Q000493:pharmacokinetics / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: D004791:Enzyme Inhibitors; D020030:Nitric Oxide Donors; D009603:Nitroso Compounds; C094210:2,2'-(hydroxynitrosohydrazono)bis-ethanamine; D009569:Nitric Oxide; D019883:Alkyl and Aryl Transferases; D051231:Farnesyltranstransferase